menu search

CATX / Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates

Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Perspective Therapeutics (CATX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.01 per share a year ago. Read More
Posted: Aug 11 2023, 10:48
Author Name: Zacks Investment Research
Views: 111820

CATX News  

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

By GlobeNewsWire
August 30, 2023

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective T h erapeutics, Inc.  (“Perspective” or “the Company”) (NYS more_horizontal

Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 11, 2023

Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates

Perspective Therapeutics (CATX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compare more_horizontal

Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)

By GlobeNewsWire
May 24, 2023

Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)

Three poster presentations from Perspective Therapeutics' scientists and collaborators explore combinations of immunotherapy and targeted alpha-partic more_horizontal


Search within

Pages Search Results: